Gryphon Financial Partners LLC Supernus Pharmaceuticals, Inc. Transaction History

Gryphon Financial Partners LLC

  • $736 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 11, 2019
SELL
$30.84 - $49.51 $124,501 - $199,871
-4,037 Closed
0 $0
Q3 2018

Nov 06, 2018
BUY
$42.7 - $56.55 $129,551 - $171,572
3,034 Added 302.49%
4,037 $204,000
Q1 2018

May 14, 2018
SELL
$37.15 - $46.9 $6,612 - $8,348
-178 Reduced 15.07%
1,003 $46,000
Q4 2017

Feb 09, 2018
BUY
$36.4 - $42.6 $42,988 - $50,310
1,181
1,181 $47,000

Others Institutions Holding SUPN

# of Institutions
281
Shares Held
60.6M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Gryphon Financial Partners LLC Portfolio

Follow Gryphon Financial Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gryphon Financial Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gryphon Financial Partners LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email